Clinical Trials: Page 11
-
Getty Images
Obesity drugsNew study offers hints of GLP-1 drugs’ potential in curbing alcohol cravings
A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed to establish a conclusive benefit.
By Jonathan Gardner • Feb. 12, 2025 -
Getty Images
Pliant shares collapse as company halts fibrosis drug study
In what one analyst called a “unique situation,” the company stopped dosing patients on the recommendation of trial monitors, but doesn’t yet know what led to their decision.
By Ben Fidler • Feb. 10, 2025 -
Explore the Trendline➔
Getty Images
TrendlineNeuroscience drug development
Enthusiasm is running higher among drugmakers and investors for neuroscience drug development, buoyed by recent approvals of new Alzheimer’s, ALS and depression medicines.
By BioPharma Dive staff -
Getty Images
Novo outlines new late-stage study of obesity drug CagriSema
CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer duration in the new trial.
By Jonathan Gardner • Feb. 5, 2025 -
Getty Images
Shares of psychedelics biotech nearly double on depression data
The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was fast and effective in a treatment-resistant depression trial.
By Jacob Bell • Feb. 3, 2025 -
Jacob Bell/BioPharma Dive
Pfizer drug acquired in $11B buyout confirms benefit in colon cancer
The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval — boosting an oncology portfolio Pfizer is looking to for revenue growth.
By Jonathan Gardner • Feb. 3, 2025 -
Getty Images
Rival radiopharma drug to Novartis’ Lutathera succeeds in trial, ITM says
ITM's lutetium-containing therapy extended progression-free survival versus everolimus in patients with a specific kind of neuroendocrine tumor.
By Ned Pagliarulo • Jan. 28, 2025 -
Getty Images
Akero says MASH drug reverses liver damage in study, doubling shares
Results showing Akero’s efruxifermin improved fibrosis by more than what Wall Street expected lifted the stock of both it and rival MASH developer 89bio.
By Ned Pagliarulo • Jan. 27, 2025 -
Getty Images
Muscle-building drug improves body composition in obesity trial, Veru says
Shares in Veru fell by nearly half following the news, despite positive results in preserving lean muscle mass.
By Jonathan Gardner • Jan. 27, 2025 -
Getty Images
Novo shares climb on early data for dual-acting obesity drug
An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts cautioned certain aspects of the study may have inflated its performance.
By Jonathan Gardner • Jan. 24, 2025 -
Getty Images
Immune resetIGM’s autoimmune pivot backfires as top drug disappoints in testing
The biotech will stop developing two drugs and lay off much of its staff after its lead therapy wasn’t as potent in early testing as the company expected.
By Ben Fidler • Jan. 9, 2025 -
Sean Gallup via Getty Images
Bayer says menopause drug succeeds in breast cancer study
The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with menopause as well as a common breast cancer therapy.
By Delilah Alvarado • Jan. 9, 2025 -
Getty Images
Metsera reveals data supporting long-acting obesity shot
The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug as a future threat to weight loss medicines from Novo Nordisk and Eli Lilly.
By Jonathan Gardner • Jan. 7, 2025 -
Mario Tama via Getty Images
J&J says cancer drug combination showed survival benefit over Tagrisso
Results from the Mariposa study found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced lung cancer live longer.
By Ned Pagliarulo • Jan. 7, 2025 -
Getty Images
ALS drug developmentALS drugs from Denali, Calico come up short, marking setback for Healey trial
Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the tally of failed drugs in the innovative “Healey platform trial” to seven.
By Jacob Bell • Jan. 7, 2025 -
Getty Images
Neumora plummets on depression drug data
The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results as a “worst-case scenario for the program.”
By Jacob Bell • Jan. 2, 2025 -
Kendall Davis/BioPharma Dive
Tracker10 clinical trials to watch the rest of 2025
Expected readouts in obesity, lung cancer and AATD headline a series of study results that could give the biotechnology sector a boost.
By BioPharma Dive staff • Updated June 30, 2025 -
Courtesy of Novo Nordisk
Novo’s next-gen obesity drug misses expectations in closely watched trial
Novo shares lost nearly a fifth of their value after an experimental combination treatment called cagrisema fell short of the bar set by executives.
By Jonathan Gardner • Updated Dec. 20, 2024 -
Getty Images
Roche sticks with Parkinson’s drug despite second study failure
Even with another mid-stage setback, Roche believes there were enough positive signs to “merit further exploration” of the drug, which it’s been developing with Prothena for more than a decade.
By Jacob Bell • Dec. 19, 2024 -
Getty Images
Regeneron says study data support big bet on new blood thinners
The company is planning a “broad Phase 3 program” for two anticoagulants after they outperformed marketed medicines in a pair of mid-stage trials.
By Jonathan Gardner • Dec. 19, 2024 -
Courtesy of Vertex Pharmaceuticals
Vertex ‘ends the year in pain’ as latest non-opioid drug data disappoint
Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ahead in the indication.
By Jacob Bell • Dec. 19, 2024 -
Getty Images
Sanofi, Teva say study results show gut disease drug could be ‘best in class’
Phase 2 results in inflammatory bowel disease hinted the therapy could be more potent than similar medicines from Merck and Roche, each of which were acquired in multibillion-dollar deals.
By Ben Fidler • Dec. 17, 2024 -
Getty Images
Maternal mortality trends are dire — and reversing them remain an uphill battle
Rising maternal mortality, particularly among vulnerable groups, has roots in insufficient research involving pregnant women.
By Michael Gibney • Dec. 17, 2024 -
Spencer Platt via Getty Images
Edgewise weighs fast approval path for muscular dystrophy drug
The biotech company will meet with regulators to discuss Phase 2 biomarker data that sent its shares climbing by more than 20% Monday.
By Ned Pagliarulo • Dec. 16, 2024 -
Getty Images
Merck calls quits on two immunotherapies for cancer
The company is scrapping two drugs aimed at targets called TIGIT and LAG-3, both of which were in the middle of Phase 3 testing.
By Jonathan Gardner • Dec. 16, 2024 -
Michael M. Santiago via Getty Images
Keros shares collapse on ‘unanticipated’ setback for lung disease drug
Safety concerns Keros observed in a Phase 2 trial triggered a stock selloff for what had been one of the sector’s most successful initial public offerings of the last four years, according to BioPharma Dive data.
By Kristin Jensen • Dec. 12, 2024
Previous
